Filing Flows › Neogenomics (NEO) › Guidance & outlook
Neogenomics (NEO) guidance and outlook
Neogenomics (NEO) raised its guidance on Oct 28, 2026.
Neogenomics' latest quarter
Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%, net loss $7.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Questions
Did Neogenomics raise or lower its guidance?
Neogenomics (NEO) raised its guidance on Oct 28, 2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.